Satellos Bioscience Granted Composition of Matter Patent for Forazapadin by USPTO

MT newswire2026/10/05 13:34

09:34 AM EDT, 10/05/2026 (MT Newswires) -- Satellos Bioscience (MSCL.TO, MSLE) was granted US Patent No. 12,747,245, entitled "AP2 associated kinase 1 inhibitors and uses thereof," by the United States Patent and Trademark Office (USPTO), it said Monday. The US patent includes composition of matter claims covering forazapadin, the company's lead clinical-stage drug candidate, and a broader class of AAK1 inhibitors and related compounds within Satellos' muscle-regeneration platform. The composition of matter provides US intellectual property protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development, it added. "As the strongest form of patent protection for a pharmaceutical product, this patent reinforces the novelty of our approach to restoring muscle regeneration and strengthens our intellectual property (IP) estate surrounding forazapadin," chief executive Frank Gleeson said. Shares of the company closed unchanged at CA$12.01 Friday on the Toronto Stock Exchange.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Only 1.45 Billion Shiba Inu (SHIB) Burned in 24 Hours Hints at Reversal

UToday•2026/10/11 10:27

Viral Altcoin Defies Market Slumber With 53% Surge, BTC Calms at $83K: Weekend Watch

Cryptopotato•2026/10/11 10:21

Global Bank Stocks Sink as Bond Losses Top $326 Billion: Is Another SVB Coming?

BeInCrypto•2026/10/11 10:06

Exclusive Report - Sources Say INWIT Investors Are Raising Funds for a Possible Privatization Deal

路透社•2026/10/11 08:51